Toralgen Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 9


  • Latest Deal Type
  • Series 1

  • Latest Deal Amount
  • $8.3M

  • Investors
  • 3

Toralgen General Information


Operator of a preclinical stage biopharmaceutical company intended to focus on the development and commercialization of human therapeutics. The company offers a poly-bile nano-particle platform that eliminates the challenges of oral delivery to fabricate nano-pill and improve outcomes through optimized and targeted drug delivery, enabling healthcare providers to improve the lives of their patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Corporate Office
  • 1220 Waterway Boulevard
  • Suite H123
  • Indianapolis, IN 46202
  • United States
+1 (317) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Toralgen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 22-Oct-2020 $8.3M 00.00 000.00 Completed Pre-Clinical Trials
To view Toralgen’s complete valuation and funding history, request access »

Toralgen Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed 2 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Seed 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Toralgen’s complete cap table history, request access »

Toralgen Executive Team (5)

Name Title Board Seat Contact Info
Gerald Rea Chief Executive Officer
David Moore Chief Operating Officer
Edward Bastyr III CMO
David Horwitz MD Co-Founder
Tarek Fahmy Ph.D Co-Founder
To view Toralgen’s complete executive team members history, request access »

Toralgen Board Members (1)

Name Representing Role Since
Tom Heniff Self Board Member 000 0000
To view Toralgen’s complete board members history, request access »

Toralgen Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Toralgen Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Elevate (Indianapolis) Venture Capital Minority 000 0000 000000 0
Solyco Capital PE/Buyout Minority 000 0000 000000 0
VisionTech Partners Angel Group Minority 000 0000 000000 0
To view Toralgen’s complete investors history, request access »

Toralgen FAQs

  • When was Toralgen founded?

    Toralgen was founded in 2017.

  • Who is the founder of Toralgen?

    David Horwitz MD and Tarek Fahmy Ph.D are the founders of Toralgen.

  • Who is the CEO of Toralgen?

    Gerald Rea is the CEO of Toralgen.

  • Where is Toralgen headquartered?

    Toralgen is headquartered in Indianapolis, IN.

  • What is the size of Toralgen?

    Toralgen has 9 total employees.

  • What industry is Toralgen in?

    Toralgen’s primary industry is Pharmaceuticals.

  • Is Toralgen a private or public company?

    Toralgen is a Private company.

  • What is the current valuation of Toralgen?

    The current valuation of Toralgen is 000.00.

  • What is Toralgen’s current revenue?

    The current revenue for Toralgen is 00000.

  • How much funding has Toralgen raised over time?

    Toralgen has raised $8.3M.

  • Who are Toralgen’s investors?

    Elevate (Indianapolis), Solyco Capital, and VisionTech Partners have invested in Toralgen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »